GALECTIN THERAPEUTICS INC — Director's Dealing 2015

Feb 3, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2015-01-31

Reporting Person: CZIRR JAMES C (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-01-31	Common stock	M	166667	$1.80	Acquired	976798	Direct
2015-01-31	Common stock	F	93168	$3.22	Disposed	883630	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-01-31	Stock option (right to buy)	$1.80	M	166667	Disposed	2015-02-01	Common stock (166667)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	2776186	Indirect

Footnotes

F1: Represents shares forfeited in satisfaction of exercise price of vested options.

F2: Reporting person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F3: Amount reflects the Issuer's 1-for-6 reverse stock split on March 23, 2012.

F4: The options are fully vested and exercisable.